查看“奥利替尼”的源代码

<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;">

    <div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;">
        <p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;">
            <strong>[[奥利替尼]]</strong>（通用名：<strong>[[Ulixertinib]]</strong>；研发代号：<strong>[[BVD-523]]</strong> / <strong>[[SCH772984]]</strong>）是一种具有口服活性的、强效且高选择性的 <strong>[[ERK1/2 抑制剂]]</strong>。作为 <strong>[[MAPK 信号通路]]</strong>（RAS-RAF-MEK-ERK）中最下游节点的“终端闸门”，奥利替尼通过直接抑制细胞外信号调节激酶（ERK）的催化活性，阻断由上游突变（如 <strong>[[KRAS]]</strong>、<strong>[[NRAS]]</strong> 或 <strong>[[BRAF V600]]</strong>）诱发的异常增殖信号。该药在解决 <strong>[[获得性耐药]]</strong>（尤其是针对 BRAF 或 MEK 抑制剂耐药后）方面具有显著的临床潜力。
        </p>
    </div>

    <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; float: right; margin: 0 0 25px 25px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;">
        
        <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #ffffff 100%); text-align: center; cursor: pointer;">
            <div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">奥利替尼 (Ulixertinib)</div>
            <div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px;">Selective ERK1/2 Inhibitor · 点击展开</div>
        </div>
        
        <div class="mw-collapsible-content">
            <div style="padding: 25px; text-align: center; background-color: #f8fafc;">
                <div style="padding: 10px; border: 1px solid #e2e8f0; border-radius: 8px; background: #fff; display: inline-block;">
                    <div style="width: 140px; height: 100px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px;">[[Ulixertinib]] [[Structure]]<br>Core Molecule</div>
                </div>
                <div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">研发机构: BioMed Valley Discoveries</div>
            </div>

            <table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;">
                <tr>
                    <th style="text-align: left; padding: 10px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 45%;">核心靶点</th>
                    <td style="padding: 10px 12px; border-bottom: 1px solid #e2e8f0; color: #b91c1c;"><strong>[[ERK1]], [[ERK2]]</strong></td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 10px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">药物类型</th>
                    <td style="padding: 10px 12px; border-bottom: 1px solid #e2e8f0;">小分子 ATP 竞争性抑制剂</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 10px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子式</th>
                    <td style="padding: 10px 12px; border-bottom: 1px solid #e2e8f0;">C<sub>21</sub>H<sub>22</sub>Cl<sub>2</sub>N<sub>6</sub>O<sub>2</sub></td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 10px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">临床阶段</th>
                    <td style="padding: 10px 12px; border-bottom: 1px solid #e2e8f0;">II/III 期临床研究</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 10px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">常用剂量</th>
                    <td style="padding: 10px 12px; border-bottom: 1px solid #e2e8f0;">600 mg (每日两次)</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 10px 12px; background-color: #f1f5f9; color: #475569;">主要适应症</th>
                    <td style="padding: 10px 12px;">晚期实体瘤 (MAPK 变异)</td>
                </tr>
            </table>
        </div>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">药理机制：锁定 MAPK 信号的终点</h2>
    <p style="margin: 15px 0; text-align: justify;">
        奥利替尼通过拦截信号级联中的最后一个激酶节点，展现了其独特的药效动力学优势：
    </p>
    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;"><strong>终端“闸门”拦截：</strong> 在 RAS-RAF-MEK-ERK 轴线中，ERK1/2 是进入细胞核调控基因表达前的必经节点。奥利替尼竞争性结合 ERK 的 <strong>[[ATP 结合口袋]]</strong>，使上游突变积累的信号无法通过。</li>
        <li style="margin-bottom: 12px;"><strong>规避负反馈调节：</strong> 上游抑制剂（如 MEK 抑制剂）常因触发反馈环导致信号再次激活。奥利替尼作用于最末端，能更彻底地抑制通路活性。</li>
        <li style="margin-bottom: 12px;"><strong>解决逃逸突变：</strong> 针对 BRAF/MEK 联用后的获得性突变（如 MEK1/2 点突变或 RAF 剪接变异），奥利替尼作为 <strong>[[挽救治疗]]</strong> 能够重新建立对通路的控制。</li>
    </ul>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床矩阵：奥利替尼的应用探索</h2>
    <div style="overflow-x: auto; margin: 30px auto;">
        <table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;">
            <tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;">
                <th style="padding: 10px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">临床方向</th>
                <th style="padding: 10px; border: 1px solid #cbd5e1; color: #475569;">患者群体描述</th>
                <th style="padding: 10px; border: 1px solid #cbd5e1; color: #1e40af;">预期临床价值</th>
                <th style="padding: 10px; border: 1px solid #cbd5e1; color: #b91c1c;">代表性研究阶段</th>
            </tr>
            <tr>
                <td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[黑色素瘤]]</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">BRAF V600 突变、MEK 抑制剂进展后</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;"><strong>克服二线耐药</strong></td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">Phase II (BVD-523-01)</td>
            </tr>
            <tr>
                <td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[非小细胞肺癌]]</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">KRAS/NRAS 突变亚型</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">联合化疗或靶向药增效</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">组合方案探索</td>
            </tr>
            <tr>
                <td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[胃肠道肿瘤]]</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">MAPK 突变、微卫星稳定 (MSS)</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">探索免疫治疗联合机会</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">概念验证研究</td>
            </tr>
        </table>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">安全性聚焦：特异性副作用监控</h2>
    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;"><strong>皮肤毒性：</strong> 与所有通路抑制剂类似，最常见的不良反应为 <strong>[[痤疮样皮疹]]</strong>。需指导患者进行预防性皮肤保护，必要时采用局部抗生素。</li>
        <li style="margin-bottom: 12px;"><strong>胃肠道反应：</strong> 包括恶心、呕吐及 <strong>[[腹泻]]</strong>。多数可通过对症支持治疗及剂量滴定方案得到缓解。</li>
        <li style="margin-bottom: 12px;"><strong>实验室异常：</strong> 需严密监测 <strong>[[肌酸磷酸激酶]]</strong> (CPK) 升高及肝酶波动。</li>
        <li style="margin-bottom: 12px;"><strong>眼部风险：</strong> 虽然较 MEK 抑制剂发生率低，但仍需警惕 <strong>[[视网膜病变]]</strong>。</li>
    </ul>

    <div style="margin: 40px 0; border: 1.2px solid #e2e8f0; border-radius: 10px; padding: 25px; background-color: #ffffff;">
        <h3 style="margin-top: 0; color: #0f172a; font-size: 1.15em; margin-bottom: 20px; border-bottom: 2px solid #3b82f6; display: inline-block; padding-bottom: 5px;">关键相关概念</h3>
        <div style="display: flex; flex-direction: column; gap: 12px; font-size: 0.95em;">
            <div style="color: #334155;"><strong style="color: #1e40af;">[[MAPK 通路]]</strong>：调控细胞生长、分化及凋亡的核心信号轴。</div>
            <div style="color: #334155;"><strong style="color: #1e40af;">[[ERK1/2]]</strong>：奥利替尼的直接靶标，也是该通路中目前最具挑战性的靶位之一。</div>
            <div style="color: #334155;"><strong style="color: #1e40af;">[[耐药逆转]]</strong>：奥利替尼设计的初衷，即解决由于上游基因逃逸引起的治疗失败。</div>
            <div style="color: #334155;"><strong style="color: #1e40af;">[[LY3214996]]</strong>：礼来公司研发的同类 ERK 抑制剂。</div>
        </div>
    </div>

    <div style="font-size: 0.9em; line-height: 1.7; color: #1e293b; margin-top: 50px; border-top: 2.5px solid #0f172a; padding-top: 25px; text-align: left;">
        <span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与行业动态</span>
        
        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [1] <strong>Sullivan RJ, et al. (2018).</strong> <em>First-in-class ERK1/2 inhibitor ulixertinib (BVD-523) in patients with advanced solid tumors.</em> <strong>[[Cancer Discovery]]</strong>. 8(2):184-195.<br>
            <span style="color: #475569;">[基础点评]：该项首入人体研究确立了奥利替尼的安全性及初步临床有效性。</span>
        </p>

        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [2] <strong>BioMed Valley Discoveries Archive (2025/2026).</strong> <em>Phase 2 efficacy data in BRAF-resistant melanoma cohorts.</em> <strong>[[ESMO Congress]]</strong>. <strong>[Academic Review]</strong>.<br>
            <span style="color: #475569;">[视角]：[Academic Review] 评述了 ERK 抑制剂作为克服“通路疲劳”的关键序贯疗法的地位。</span>
        </p>
    </div>

    <div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;">
        <div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: left; border-bottom: 1px solid #dbeafe;">
            MAPK 靶向治疗图谱 · 知识图谱
        </div>
        <table style="width: 100%; border-collapse: collapse; background-color: #ffffff;">
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 100px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 15px; text-align: left; vertical-align: middle;">上游通路</td>
                <td style="padding: 10px 15px; color: #334155; text-align: left;">[[威罗菲尼]] (BRAFi) • [[曲美替尼]] (MEKi) • [[索托拉西布]] (KRASi)</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 100px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 15px; text-align: left; vertical-align: middle;">奥利替尼定位</td>
                <td style="padding: 10px 15px; color: #334155; text-align: left;">[[ERK1/2 抑制]] • [[耐药后补救治疗]] • [[组合免疫疗法]]</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 100px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 15px; text-align: left; vertical-align: middle;">关键监控</td>
                <td style="padding: 10px 12px; color: #334155; text-align: left;">[[痤疮样皮疹处理]] • [[CPK 水平监测]] • [[下级底物磷酸化检测]]</td>
            </tr>
        </table>
    </div>

</div>